Drug

Target

Treatment Line

ORR

mPFS

1G: Gefitinib (Iressa^®)

EGFRmut

1^st line

71.6%

9.2 months¹

1G: Erlotinib (Tarceva^®)

EGFRmut

1^st line

54.5%

10.4 months²

2G: Afatinib (Giotrif^®)

EGFRmut

1^st line

67.8%

11.0 months³

2G: Dacomitinib (Vizimpro^®)

EGFRmut

1^st line

74.9%

14.7 months¹

3G: Osimertinib (Tagrisso^®)

EGFRmut

1^st line

2^nd line

80%

71%

18.9 months⁴

10.1 months⁵

1G: Crizotinib (Xalkori^®)

ALK

1^st line

2^nd line

74%

65%

10.9 months⁶

7.7 months⁷

2G: Ceritinib (Zykladia^®)

ALK

1^st line

2^nd line

72.5%

39.1%

16.6 months⁸

5.4 months⁹

3G: Alectinib (Alecensa^®)

ALK

1^st line

2^nd line

82.9%

51%

25.7 months¹⁰

8.3 months¹¹

3G: Brigatinib (Alunbrig^®)

ALK

1^st line

2^nd line

73.7%

56%

24 months¹²

16.7 months¹³

4G: Lorlatinib (Lorviqua^®)

ALK

2^nd line

42.9%

5.5 months¹⁴

1G: Selpercatinib (Retsevmo^®)

RET

1^st line

63.8%

17.5 months¹⁵

1G: Pralsetinib (Gavreto^®)

RET

1^st line

70%

9.0 months¹⁶